52-week high: $4.02
Current price: $2.28
Year-to-date performance relative to the Nasdaq Biotechnology Index: Up 39% Shorts believe BioSante's Libigel is nothing more than a me-too, low-dose formulation of testosterone being developed for the disease-mongering indication of female sexual dysfunction. A female Viagra this isn't, which is why deep-pocketed Big Pharma is steering clear. >>To see these stocks in action, visit the 10 Most Shorted Stocks in Biotech portfolio on Stockpickr. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.